TABLE OF CONTENTS

In This Issue/Research Watch/News in Brief .......................................................... 1055
From the IASLC Tobacco Control Committee ...................................................... 1060

EDITORIALS

Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase
Inhibitors .................................................................................................................. 1063
Tsung-Che Wu, MD, and Chia-Chi Lin, MD, PhD

EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of
Old Tools to the Integration of New Agents ........................................................ 1067
Nicolas Girard, MD, PhD

Determining Whether YAP1 and POU2F3 Are Antineuroendocrine
Factors .................................................................................................................... 1070
Ryota Matsuoka, PhD, MD, Hitomi Kawai, PhD, MD, Takeshi Ito, PhD, and
Daisuke Matsubara, MD, PhD

About the Cover: the cover image is from Figure 5 in the article by Baine
on page 1109.

denotes online only article
OPEN ACCESS denotes Open Access article

(continued on next page)
EDITORIAL: LUNG CANCER WORLDWIDE

Lung Cancer in Rwanda
Brandon A. Niyibizi, BPharm, Eulade Muhizi, MD, Diana A. Ndoli, MD, Ivan Rukundo, MD, Thierry Z. Muvunyi, MD, Maurice Musoni, MD, Damas Dukundane, MD, Emmanuel Rudakemwa, MD, Fidel Rubagumya, MD, and Achille Van Christ Manirakiza, MD, MMed

ORIGINAL ARTICLES

Translational Oncology

Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC
Aileen I. Fernandez, PhD, Niki Gavrielatou, MD, Leena McCann, BS, Saba Shaﬁ, MD, Myrto K. Moutaﬁ, MD, Sandra Martinez-Morilla, PhD, Ioannis A. Vathiotis, MD, Thazin Nwe Aung, PhD, Vesal Yaghoobi, MD, Yalai Bai, MD, Yvonne G. Chan, PhD, Jodi Weidler, PhD, Roy Herbst, MD, PhD, Michael Bates, MD, and David L. Rimm, MD, PhD

Non-small Cell Lung Cancer

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Maria Carmela Piccirillo, MD, Laura Bonanno, MD, Marina Chiara Garassino, MD, Marco Angelo Burgio, MD, Francesco Rosetti, MD, Simona Rizzato, MD, Floriana Morgillo, PhD, Saverio Cinieri, MD, Antonello Veccia, MD, Maximilan Papi, MD, Giuseppe Tonini, PhD, Vittorio Gebbìa, PhD, Serena Ricciardi, MD, Daniele Ponzessere, MD, Alessandra Ferro, MD, Claudia Proto, MD, Raffaele Costanzo, MD, Manolo D’Arcangelo, MD, Manuela Proietto, MD, Piera Gargiulo, MD, Raimondo Di Liello, MD, Laura Arenare, MSc, Filippo De Marinis, MD, Lucio Crinò, MD, Fortunato Ciardiello, PhD, Nicola Normanno, MD, Ciro Gallo, MD, Francesco Perrone, PhD, Cesare Gridelli, MD, and Alessandro Morabito, MD

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu, MD, PhD, Kazushige Wakuuda, MD, Keita Mori, PhD, Terufumi Kato, MD, Shunichi Sugawara, MD, PhD, Keisuke Kiritia, MD, PhD, Yasuto Yoneshima, MD, PhD, Koichi Azuma, MD, PhD, Kazumi Nishino, MD, PhD, Shunsuke Teraoka, MD, Takehito Shukuya, MD, PhD, Ken Masuda, MD, PhD, Hidetoshi Hayashi, MD, PhD, Ryo Toyozawa, MD, Satoru Miura, MD, PhD, Daichi Fujimoto, MD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, and Toshiaki Takahashi, MD, PhD

(continued on next page)
Small Cell Lung Cancer

POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC............................................... 1109
Marina K. Baine, MD, PhD, Christopher A. Febres-Aldana, MD, Jason C. Chang, MD, Achim A. Jungbluth, MD, PhD, Shenon Sethi, MD, Cristina R. Antonescu, MD, William D. Travis, MD, Min-Shu Hsieh, MD, PhD, Mee Sook Roh, MD, PhD, Robert J. Homer, MD, PhD, Marc Ladanyi, MD, Jacklynn V. Egger, BS, W. Victoria Lai, MD, Charles M. Rudin, MD, PhD, and Natasha Rekhtman, MD, PhD

BRIEF REPORTS

Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.................................................................................................... 1122
Martin Reck, MD, PhD, Tony S. K. Mok, MD, Aaron Mansfield, MD, Richard De Boer, MBBS, FRACP, Gyorgy Losonczy, MD, PhD, DSc, Shunichi Sugawara, MD, PhD, Maciej Krzakowski, MD, Alexey Smolin, MD, Maximilian Hochmair, MD, Marina Chiara Garassino, MD, Gilberto de Castro Junior, MD, Helge Bischoff, MD, Sivuonthan Lam, PharmD, Andres Cardona, MSc, Stefanie Morris, PhD, and Stephen V. Liu, MD

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.............................................................................................. 1130
Or Kalchiem-Dekel, MD, Christina J. Falcon, MPH, Christine M. Bestvina, MD, Dazhi Liu, PharmD, Lauren A. Kaplanis, BSN, Clare Wilhelm, PhD, Jordan Eichholz, BA, Guilherme Harada, MD, Lori J. Wirth, MD, Subba R. Digumarthy, MD, Robert P. Lee, MD, David Kadosh, MD, Robin B. Mendelsohn, MD, Jessica Donington, MD, Justin F. Gainor, MD, Alexander Drilon, MD, and Jessica J. Lin, MD

LETTERS TO THE EDITOR

Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC ................................................................................................................. e71
Binghao Zhao, MD, PhD, Huanzhang Li, MD, and Wenbin Ma, MD

A Response to the Letter to the Editor: “Bevacizumab Plus Atezolizumab in Pretreated Progressive and Non-Small Cell Lung Cancer”........ e72
Jiyun Lee, MD, PhD, and Myung-Ju Ahn, MD, PhD

Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?.. e73
Marco Chiappetta, MD, Carolina Sassorossi, MD, Diomira Tabacco, MD, Filippo Lococo, MD, and Stefano Margaritora, MD

Comment on “Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?”......................................................... e74
Junghee Lee, MD, PhD, Yun Soo Hong, MD, MHS, Juhee Cho, MA, PhD, Jin Lee, MPH, and Hong Kwan Kim, MD, PhD

Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations............................... e76
Binghao Zhao, MD, Hao Xing, MD, and Wenbin Ma, MD

(continued on next page)
TABLE OF CONTENTS (continued)

C Reply to Binghao Zhao et al................................................................. e77
  Hirotsugu Kenmotsu, MD, PhD, Keita Mori, PhD, Kazuhiko Nakagawa, MD, PhD,
  Nobuyuki Yamamoto, MD, PhD, and Toshiaki Takahashi, MD, PhD

C Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer ......................................................................................... e79
  Manana Javey, MD, PhD, and Stephanie J. Yaung, PhD

C 2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification ................................................. e80
  Andrew G. Nicholson, DM, Giorgio Scagliotti, MD, Ming Sound Tsao, MD, FRCPC,
  Yasushi Yatabe, MD, and William D. Travis, MD

C Nontumor cells in Tumor Specimens Impair the Accuracy of Quantitative Polymerase Chain Reaction in the Detection of Programmed Death-Ligand 1 Copy Number Variant and mRNA Expression ............................................. e83
  Huan Zhang, MD, Zhencong Chen, MD, Ming Li, MD, Qihai Sui, MD, and
  Cheng Zhan, PhD

C Response to “Non-Tumor Cells in Tumor Specimens Impair the Accuracy of qPCR in the Detection of PD-L1 CNV and mRNA Expression” ............. e84
  Steven Bozinovski, PhD

C Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered ............ e85
  Binghao Zhao, MD, PhD, and Wenbin Ma, MD

C In Response to Continuation of Lorlatinib Beyond Progressive Disease ........................................................................................................ e86
  Sai-Hong Ignatius Ou, MD, PhD

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works: Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company.

For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage: Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions: For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843800 (UK) / (+1) 215 239 3804 (USA).

Author rights: Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorrights).

Notice: The statements and opinions contained in the material herein are solely those of the individual authors and contributors and not those of the International Association for the Study of Lung Cancer or Elsevier Inc. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher or the IASLC for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, please contact Derrick Imasa, Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, New York, NY 10169; phone (212) 633-3874; fax (212) 462-1935; e-mail: reprints@elsevier.com.

For advertising orders and inquiries: North and South America: Courtney Leonard, Elsevier Inc., 230 Park Avenue, New York, NY 10169; phone (732) 779-3368; e-mail: c.leonard@elsevier.com. Europe/ROW: Robert Bayliss, Elsevier Inc., 125 London Wall, London, EC2Y 5AS, UK; phone (+44) 20 7424 4454; e-mail: r.bayliss@elsevier.com.

Journal of Thoracic Oncology is indexed in Current Contents/Clinical Medicine, Science Citation Index Expanded (SCI-EXPANDED), Journal Citation Reports/Science Edition, and MEDLINE.